Silence Therapeutics earnings release, August 10, 2026

Silence Therapeutics plc (SLN) · Form 8-K, Item 2.02 · Filed · SEC filing

Silence Therapeutics Reports Second Quarter 2026 Financial and Business Results

10 August 2026

LONDON, Silence Therapeutics plc, (Nasdaq:

SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today reported its financial and business results for the second quarter ended June 30, 2026.

Business Highlights

Divesiran:

First-in-class siRNA silencing TMPRSS6 for polycythemia vera (PV) and other blood disorders

SLN312 (AZD1705): Phase 1 siRNA silencing ANGPTL3 with a competitive profile for dyslipidemia

Pre-clinical pipeline updates:

Second Quarter 2026 Financial Results

About Silence Therapeutics

Silence Therapeutics is a global clinical-stage biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines created with proprietary siRNA (short interfering RNA) technology. Silence leverages its mRNAi GOLD™ platform to create innovative siRNA therapies designed to precisely target and silence genes that cause disease. The Company is advancing a growing pipeline of siRNA product candidates targeting areas of high unmet need across rare and common diseases where treatments are limited or inadequate. For more information, please visit https://www.silence-therapeutics.com/.

Financial statements

Income Statement

Three months ended June 30, — (Unaudited, in thousands, except share and per share data)

Three months ended June 30, – 2026Three months ended June 30, – 2025Six months ended June 30, – 2026Six months ended June 30, – 2025
Revenue$—224422366
Cost of sales-85-11-139
Gross profit139411227
Research and development costs-9,148-17,647-18,270-38,460
General and administrative expenses-4,717-5,131-11,743-12,815
Restructuring charges-1,324-1,324
Operating loss-13,865-23,963-29,602-52,372
Foreign currency gain/(loss), net151-6,613-331-10,382
Other income, net6698611,2401,830
Benefit from R&D credit7782,3711,4695,050
Loss before income tax expense-12,267-27,344-27,224-55,874
Income tax expense-1-10-1-10
Net Loss-12,268-27,354-27,225-55,884
Loss per share (basic and diluted)-0.09-0.19-0.19-0.39
Weighted average shares outstanding (basic and diluted)141,709,762141,696,047141,706,190141,687,438

Balance Sheet

June 30, 2026 — (Unaudited, in thousands, except share and per share data)

June 30, 2026December 31, 2025
Current assetsCash and cash equivalents72,05411,277
Current assetsShort-term investments73,837
Current assetsR&D benefit receivable9,29222,007
Current assetsOther current assets12,93511,537
Current assetsTotal current assets94,281118,658
Current assetsProperty, plant and equipment1,3251,581
Current assetsOperating lease right-of-use assets117167
Current assetsGoodwill10,32510,621
Current assetsOther intangible assets237288
Current assetsOther long-term assets127127
Current assetsTotal assets106,412131,442
Current liabilitiesContract liabilities$—-168
Current liabilitiesTrade and other payables-12,611-13,356
Current liabilitiesOperating lease liabilities, current-103-89
Current liabilitiesTotal current liabilities-12,714-13,613
Current liabilitiesContract liabilities-55,218-55,454
Current liabilitiesOperating lease liabilities-9-71
Current liabilitiesTotal liabilities-67,941-69,138
Shareholders’ equityOrdinary shares - par value £0.05 per share; 141,739,180 shares issued at June 30, 2026 (December 31, 2025: 141,701,848)-10,292-10,290
Shareholders’ equityAdditional paid-in capital-621,152-617,562
Shareholders’ equityAccumulated deficit589,632562,572
Shareholders’ equityAccumulated other comprehensive loss3,3412,976
Shareholders’ equityTotal shareholders’ equity-38,471-62,304
Shareholders’ equityTotal liabilities and shareholders’ equity-106,412-131,442
Full release

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, you can identify forward-looking statements by terminology such as “aim,” “anticipate,” “assume,” “believe,”

“contemplate,” “continue,” “could,” “design,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,”

“plan,” “positioned,” “potential,” “predict,” “seek,” “should,” “target,” “will,” “would” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. All statements other than statements of historical facts contained in this press release are forward-looking statements. These forward-looking statements include, but are not limited to, statements about: the Company’s business strategy and plans, including the Company’s clinical development activities and timelines; the potential therapeutic benefits of the

Company’s product candidates; and the anticipated timing of initial topline and future results from the SANRECO Phase 2 trial. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, risks and uncertainties related to: the company’s history of net operating losses; the company’s ability to obtain necessary capital to fund its clinical programs; the early stages of clinical development of the company’s product candidates; the Company’s ability to obtain regulatory approval of and successfully commercialize its product candidates either on its own or with potential partners; any undesirable side effects or other properties of the company’s product candidates; the Company’s reliance on third-party suppliers and manufacturers; the outcomes of any future collaboration agreements; and the Company’s ability to adequately maintain intellectual property rights for its product candidates. These and other risks are described in greater detail under the section titled “Risk Factors” contained in the Company’s Annual Report on Form

10-K and Quarterly Reports on Form

10-Q and the Company’s other filings with the SEC. Any forward-looking statements that the Company makes in this press release are made pursuant to the Private Securities Litigation Reform Act of 1995, as amended, and speak only as of the date of this press release. Except as required by law, the Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.

Inquiries:

Silence Therapeutics plc

Gem Hopkins, VP, Head of IR and Corporate Communications

Tel: +1 (646)

637-3208 ir@silence-therapeutics.com

Silence Therapeutics plc

Condensed Consolidated Statements of Operations

(Unaudited, in thousands, except share and per share data)

Silence Therapeutics plc

Condensed Consolidated Balance Sheets

(Unaudited, in thousands, except share and per share data)

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Silence Therapeutics earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.